Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

Blueprint Medicines Corporation (BPMC) reported first-quarter 2025 adjusted loss of 74 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 42 cents. The adjusted figure excludes the one-time equity investment gain of $50 million recorded in the reported quarter, following the closing of GSK's acquisition of IDRx. The company incurred a loss of$1.32 per share in the year-ago quarter.Quarterly revenues of $149.4 million, generated entirely from the net product sales of Ayvakit, mi ...